A61K 47/68037
The drug being a camptothecin [cpt] or derivatives
Official title: {the drug being a camptothecin [CPT] or derivatives}
A61K47/68037 (The drug being a camptothecin [cpt] or derivatives) appears on 244 US grants and 806 published applications in this corpus.
Search patents in A61K- Granted patents
- 244
- Published applications
- 806
- Assignees
- 253
- Inventors
- 1,728
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 2 | 1 |
| 2010 | 0 | 2 |
| 2011 | 2 | 4 |
| 2012 | 2 | 3 |
| 2013 | 5 | 5 |
| 2014 | 5 | 13 |
| 2015 | 9 | 26 |
| 2016 | 18 | 21 |
| 2017 | 13 | 22 |
| 2018 | 16 | 20 |
| 2019 | 12 | 24 |
| 2020 | 13 | 19 |
| 2021 | 19 | 30 |
| 2022 | 10 | 29 |
| 2023 | 20 | 78 |
| 2024 | 24 | 137 |
| 2025 | 37 | 189 |
| 2026 | 36 | 180 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- Antibody, antibody-drug conjugate thereof and use thereof22 Sep 2026US 12,742,009 B2Evopoint Biosciences Co., Ltd.
- Antibody-drug conjugates and their uses15 Sep 2026US 12,734,244 B2Mablink Bioscience
- Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof8 Sep 2026US 12,728,168 B2Jiangsu Hengrui Medicine Co., Ltd.
- Camptothecin drug conjugate and use thereof8 Oct 2026US 2026/0306650 A1Shanghai Zaimo Biotechnology Co., Ltd.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Conjugates comprising cleavable linkers8 Oct 2026US 2026/0306654 A1AstraZeneca AB
- Antibody-drug conjucates employing novel linker-payload systems for enhanced targeting of cancer-associated glycan antigens8 Oct 2026US 2026/0306655 A1BioNTech SE
- Modified antibodies, antibody fragments thereof, and antibody-drug conjugates1 Oct 2026US 2026/0295063 A1Innovent Biologics (Suzhou) Co., Ltd.
Most cited
By later US patents
- Immunoconjugates with an intracellularly-cleavable linkage120US 7,585,491 B2Immunomedics, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Immunoconjugates with an intracellularly-cleavable linkage81US 8,425,912 B2Immunomedics, Inc. · 2013